Anasuya Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anasuya Pal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anang A. Shelat
Department of Chemical Biology & Therapeutics MS 1000 St. Jude Children's Research Hospital Memphis TN USA
1 shared publication - Caroline Buchholz
Department of Chemistry, University of Minnesota, 207 Pleasant St. SE, Minneapolis, MN, 55455, USA
1 shared publication - Chun-Ju Tsou
Department of Chemistry University of Minnesota Minneapolis Minnesota USA
1 shared publication - Kesavan Babu
Department of Chemical Biology & Therapeutics MS 1000 St. Jude Children's Research Hospital Memphis TN USA
1 shared publication - Liying Fan
Department of Chemical Biology & Therapeutics, MS 1000, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA
1 shared publication - Marcus Fischer
Department of Chemical Biology & Therapeutics MS 1000 St. Jude Children's Research Hospital Memphis TN USA
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma
Bromodomain PHD finger Transcription Factor (BPTF) is an epigenetic regulator implicated in cancer progression. However, despite its oncogenic significance, highly selective and potent inhibitors of the BPTF bromodomain (BRD) with suitable physicochemical properties are lacking. Previously, we reported BZ1, a submicromolar BPTF inhibitor which has off-target activities. Here, we applied comparative structural biology and molecular modeling to design BZ2, a regioisomer of BZ1 with enhanced selectivity for BPTF over other class I bromodomains and class-IV BRDs such as BRD7 and BRD9. Co-crystal structures and computational analyses reveal that differential engagement of water networks and polar interactions drives this selectivity. Functional studies demonstrate that genetic disruption of the BPTF BRD or treatment with BZ2 suppresses neuroblastoma cell growth. With high potency and improved physicochemical properties, BZ2 provides a valuable tool for probing the biology of BPTF and represents a promising starting point for advancing BPTF-targeted drug development.
- 14 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDifferential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma
Bromodomain PHD finger Transcription Factor (BPTF) is an epigenetic regulator implicated in cancer progression. However, despite its oncogenic significance, highly selective and potent inhibitors of the BPTF bromodomain (BRD) with suitable physicochemical properties are lacking. Previously, we reported BZ1, a submicromolar BPTF inhibitor which has off-target activities. Here, we applied comparative structural biology and molecular modeling to design BZ2, a regioisomer of BZ1 with enhanced selectivity for BPTF over other class I bromodomains and class-IV BRDs such as BRD7 and BRD9. Co-crystal structures and computational analyses reveal that differential engagement of water networks and polar interactions drives this selectivity. Functional studies demonstrate that genetic disruption of the BPTF BRD or treatment with BZ2 suppresses neuroblastoma cell growth. With high potency and improved physicochemical properties, BZ2 provides a valuable tool for probing the biology of BPTF and represents a promising starting point for advancing BPTF-targeted drug development.